icon-folder.gif   Conference Reports for NATAP  
 
  International HIV and Hepatitis Drug Resistance Workshop
June 8-12, 2010,
Dubrovnik Croatia
Back grey_arrow_rt.gif
 
 
 
Long-term Follow-up of Patients Treated with Boceprevir in Combination with PEG-Intron/Ribavirin (P/R): Durability of Responses and Rates of Reversion of Resistance Mutations
 
 
  Reported by Jules Levin
International HIV and Hepatitis Drug Resistance Workshop, June 8-12, 2010,
Dubrovnik, Croatia
 
R. Ralston, J. Vierling, E. Lawitz, J. McCone, S. Gordon, D. Pound,
M. Davis, J. Galati, I. Jacobson, L. Rossaro, F. Anderson, J. King,
W. Cassidy, M. Bourliere, R. Esteban-Mur, N. Ravendhran,
G. Galler, J. Long, N. Boparai, P. Mendez, C. Brass, J. Albrecht
Supported by Schering-Plough Corporation, now Merck & Co. Inc., Whitehouse Station, N.J., U.S.A.
 
This information is property of Merck, used only with permission.